You just read:

Semaglutide Demonstrated Superior Improvements in Glycaemic Control vs Sitagliptin (SUSTAIN 2) and Exenatide ER (SUSTAIN 3) in Two Clinical Trials in Adults With Type 2 Diabetes

News provided by

Novo Nordisk

12 Jun, 2016, 15:15 BST